Home Cart Sign in  
Chemical Structure| 379270-38-9 Chemical Structure| 379270-38-9

Structure of Tenofovir alafenamide fumarate
CAS No.: 379270-38-9

Chemical Structure| 379270-38-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GS-7340 Fumarate, the prodrug of tenofovir, is a reverse transcriptase inhibitor that can prevent HIV from multiplying.

Synonyms: GS-7340 fumarate; TAF fumarate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tenofovir alafenamide fumarate

CAS No. :379270-38-9
Formula : C25H33N6O9P
M.W : 592.54
SMILES Code : C[C@H](N[P@@](OC1=CC=CC=C1)(CO[C@H](C)CN2C=NC3=C(N)N=CN=C23)=O)C(OC(C)C)=O.O=C(O)/C=C/C(O)=O
Synonyms :
GS-7340 fumarate; TAF fumarate
MDL No. :MFCD28167823

Safety of Tenofovir alafenamide fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Jurkat cells 10 μM to 2.1 pM 48 h To evaluate the effect of AZD5582 on HIV transcription in Jurkat cells, the results showed that AZD5582 effectively induced HIV transcription. PMC7111210
HEK293T cells 1000 ng/mL 1 h To evaluate the binding ability of PG16-Db and 3BNC117-Db to the Env protein on the surface of HEK293T cells. The results showed that PG16-Db and 3BNC117-Db could bind to the Env protein on the surface of HEK293T cells. PMC10907297
ACH-2 cells 10-1000 pM 6 h To evaluate the ability of PG16-Db and 3BNC117-Db to induce NK cell activation in ACH-2 cells. The results showed that PG16-Db and 3BNC117-Db induced NK cell degranulation and the release of effector molecules in the presence of ACH-2 cells. PMC10907297
CD4+ T cells 0.2 µg/ml 5 days To evaluate the ability of Bi-Ab32/16 to induce ADCC responses in HIV-infected CD4+ T cells. Results showed that Bi-Ab32/16 significantly reduced HIV-infected CD4+ T cells, indicating its effectiveness in clearing HIV-infected cells. PMC11829058
CEM NKR CCR5+ cells 0.2 µg/ml 4.5 h To evaluate the ability of Bi-Ab32/16 to induce NK cell activation and ADCC responses in HIV-infected cells. Results showed that Bi-Ab32/16 significantly enhanced IFN-γ and CD107a expression in NK cells, indicating its ability to effectively induce cytotoxic responses. PMC11829058

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice BLT mouse model Oral 1560 mg/kg For 5 weeks Evaluate the impact of Tenofovir on HIV persistence during ART PMC9975043
Mice Humanized MISTRG-6-15 mice Oral 1 g/kg Continuous administration Suppress HIV-1 replication PMC9753998
Mice Chronic unpredictable mild stress model Gastric administration 30 mg/kg Once daily for 2 weeks Tenofovir significantly reversed chronic stress-induced negative emotional behaviors, improving anxiety and depression-like behaviors in mice. PMC9933381
Mice Pregnant mice Oral gavage 100 mg/kg Once daily for 5 days To test the effect of reverse transcriptase inhibitors on HSC activation and erythropoiesis in pregnant mice. Results showed that treatment with reverse transcriptase inhibitors in pregnant mice reduced red blood cell counts, decreased HSC frequency in the bone marrow and spleen, and reduced erythropoiesis. PMC11709122
DRAGA mice HIV infection model Oral 5.35mg Once daily for 42 days Evaluate the efficacy of antiretroviral therapy PMC9732419
Rhesus macaques SIV-infected rhesus macaque model Subcutaneous injection 5.1 mg/mL Once daily for 55 to 67 weeks To evaluate the antiviral effect of Tenofovir in the SIV-infected rhesus macaque model, the results showed that Tenofovir effectively suppressed SIV replication. PMC7111210
Mice HIL-15TgNSG mouse model Intraperitoneal injection 200 μg Once daily for 10 days To evaluate the ability of 3BNC117-Db to enhance NK cell activity and reduce the HIV-1 reservoir in a mouse model. The results showed that 3BNC117-Db significantly enhanced NK cell activity and reduced the reservoir size. PMC10907297
NSG-hu-IL-15 mice HIV infection model Intraperitoneal injection 500 µg/mouse Twice a week for 2 weeks To evaluate the antiviral efficacy of Bi-Ab32/16 in an HIV-infected mouse model. Results showed that the Bi-Ab32/16-treated group experienced viral rebound after ART interruption, and a significant decline in NK cell numbers was observed, indicating potential NK cell depletion. PMC11829058
BLT mice HIV infection model Intravenous injection 10 million T cells Once a week for 3 weeks To evaluate the effect of IL-7 and IL-15 on CAR T cell persistence, results showed that IL-7/IL-15 cultured CAR T cells had modestly improved persistence during chronic HIV infection PMC11163220
Mice Humanized mouse model of HIV-1 infection Oral 90 mg/kg Daily for seven weeks Suppress HIV-1 viral replication PMC10518630

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05195450 Non-cirrhotic, Chronic Hepatit... More >>is B Less << RECRUITING 2027-12-31 Institute of Liver & Biliary S... More >>ciences (ILBS), New Delhi, Delhi, 110070, India Less <<
NCT02957994 Hepatitis B PHASE4 UNKNOWN 2017-11-01 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.69mL

0.34mL

0.17mL

8.44mL

1.69mL

0.84mL

16.88mL

3.38mL

1.69mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories